Short- and Long-Term Complications of Therapy for Testicular Cancer

Urologic Clinics of North America

Volumn 34, Issue 2, 2007, Pages 259-268

  Kaufman, Melissa R ^a   Chang, Sam S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CORTICOSTEROID; ETOPOSIDE; IFOSFAMIDE; ONDANSETRON; TUMOR MARKER; VINBLASTINE;

ABDOMINAL WALL HERNIA; ANOREXIA; BLEEDING; BLOOD VESSEL INJURY; BONE NECROSIS; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURVIVOR; CANCER THERAPY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CHYLOUS ASCITES; DIARRHEA; DRUG WITHDRAWAL; EJACULATION DISORDER; ENDOCRINE DISEASE; FATIGUE; GERM CELL TUMOR; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; HYPOMAGNESEMIA; INTESTINE OBSTRUCTION; LEUKEMIA; LOW DRUG DOSE; LUNG TOXICITY; LYMPH NODE DISSECTION; LYMPHOCELE; MALE INFERTILITY; METABOLIC DISORDER; MORBIDITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORCHIECTOMY; OTOTOXICITY; PATIENT COUNSELING; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; RAYNAUD PHENOMENON; REVIEW; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SURGICAL INFECTION; TESTIS CANCER; THROMBOEMBOLISM; URETER INJURY; VASCULAR DISEASE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; RISK FACTORS; SURVIVAL RATE; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247557452     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.02.011     Document Type: Review

References (118)

1. Bosl G.J., and Motzer R.J. Testicular germ-cell cancer. N Engl J Med 337 (1997) 242-253
2. Oliver R.T. Testis cancer. Curr Opin Oncol 9 (1997) 287-294
3. Huyghe E., Matsuda T., and Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 170 (2003) 5-11
4. McKiernan J.M., Goluboff E.T., Liberson G.L., et al. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol 162 (1999) 361-363
5. Carver B.S., and Sheinfeld J. Germ cell tumors of the testis. Ann Surg Oncol 12 (2005) 871-880
6. International germ cell consensus classification. A prognostic factor-based staging system for metastatic germ cell cancers. International germ cell cancer collaborative group. J Clin Oncol 15 (1997) 594-603
7. Abouassaly R., Klein E.A., and Raghavan D. Complications of surgery and chemotherapy for testicular cancer. Urol Oncol 23 (2005) 447-455
8. Grossfeld G.D., and Small E.J. Long-term side effects of treatment for testis cancer. Urol Clin North Am 25 (1998) 503-515
9. Richie J.P., and Steele G.S. Neoplasms of the testis. In: Walsh P.C. (Ed). Campbell's urology, Eighth Edition (2002), Saunders, Philadelphia 2876-2919
10. Sheinfeld J., McKiernan J., and Bosl G.J. Surgery of testicular tumors. In: Walsh P.C. (Ed). Campbell's urology, Eighth Edition (2002), Saunders, Philadelphia 920-944
11. Bochner B.H., Lerner S.P., Kawachi M., et al. Postradical orchiectomy hemorrhage: should an alteration in staging strategy for testicular cancer be considered?. Urology 46 (1995) 408-411
12. Capelouto C.C., Clark P.E., Ransil B.J., et al. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary?. J Urol 153 (1995) 981-985
13. Leibovitch I., Baniel J., Foster R.S., et al. The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. J Urol 154 (1995) 935-939
14. Giguere J.K., Stablein D.M., Spaulding J.T., et al. The clinical significance of unconventional orchiectomy approaches in testicular cancer: a report from the testicular cancer intergroup study. J Urol 139 (1988) 1225-1228
15. van Basten J.P., Jonker-Pool G., van Driel M.F., et al. Fantasies and facts of the testes. Br J Urol 78 (1996) 756-762
16. Fleer J., Hoekstra H.J., Sleijfer D.T., et al. Quality of life of survivors of testicular germ cell cancer: a review of the literature. Support Care Cancer 12 (2004) 476-486
17. Chapple A., and McPherson A. The decision to have a prosthesis: a qualitative study of men with testicular cancer. Psychooncology 13 (2004) 654-664
18. Herrinton L.J., Brox T., Greenland S., et al. Regarding: a cohort study of systemic and local complications following implantation of testicular prostheses. Ann Epidemiol 13 (2003) 73-77
19. Turek P.J., and Master V.A. Safety and effectiveness of a new saline-filled testicular prosthesis. J Urol 172 (2004) 1427-1430
20. Sternberg C.N. The management of stage I testis cancer. Urol Clin North Am 25 (1998) 435-449
21. Klepp O., Olsson A.M., Henrikson H., et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian testicular cancer group. J Clin Oncol 8 (1990) 509-518
22. Lashley D.B., and Lowe B.A. A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 25 (1998) 405-423
23. Whitmore W. Some experience with retroperitoneal lymph node dissection and chemotherapy in the management of testis neoplasms. Br J Urol 34 (1962) 436-447
24. Skinner D.G., and Leadbetter W.F. The surgical management of testis tumors. J Urol 106 (1971) 84-93
25. Donohue J.P., Zachary J.M., and Maynard B.R. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128 (1982) 315-320
26. Weissbach L., and Boedefeld E.A. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. Urol 138 (1987) 77-82
27. Weinstein M. Lymphatic drainage of the testes. Atlas Urol Clin North Am 7 (1999) 1-7
28. Donohue J.P., and Rowland R.G. Complications of retroperitoneal lymph node dissection. J Urol 125 (1981) 338-340
29. Donohue J.P. Nerve-sparing retroperitoneal lymphadenectomy for testis cancer. Evolution of surgical templates for low-stage disease. Eur Urol 23 (1993) (Suppl 2):44-46
30. Donohue J.P., Thornhill J.A., Foster R.S., et al. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol 71 (1993) 326-335
31. Foster R.S., and Donohue J.P. Nerve-sparing retroperitoneal lymphadenectomy. Urol Clin North Am 20 (1993) 117-125
32. Baniel J., and Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol 17 (1999) 263-267
33. Patel A. Complications of lymphadenectomy. In: Taneja S., Smith R., and Ehrlich R. (Eds). Complications of urologic surgery (2001), Saunders, Philadelphia 370-386
34. Baniel J., Foster R.S., Rowland R.G., et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153 (1995) 976-980
35. Donohue J.P. Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection. Urol Clin North Am 4 (1977) 509-521
36. Hoeltl W., Hruby W., and Aharinejad S. Renal vein anatomy and its implications for retroperitoneal surgery. J Urol 143 (1990) 1108-1114
37. Heidenreich A., Albers P., Hartmann M., et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German testicular cancer study group. J Urol 169 (2003) 1710-1714
38. Babaian R.J., Bracken R.B., and Johnson D.E. Complications of transabdominal retroperitoneal lymphadenectomy. Urology 17 (1981) 126-128
39. Karcaaltincaba M., and Akhan O. Radiologic imaging and percutaneous treatment of pelvic lymphocele. Eur J Radiol 55 (2005) 340-354
40. Baniel J., Foster R.S., Rowland R.G., et al. Management of chylous ascites after retroperitoneal lymph node dissection for testicular cancer. J Urol 150 (1993) 1422-1424
41. Shapiro A.M., Bain V.G., Sigalet D.L., et al. Rapid resolution of chylous ascites after liver transplantation using somatostatin analog and total parenteral nutrition. Transplantation 61 (1996) 1410-1411
42. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 338S-400S
43. Baniel J., Leibovitch I., Foster R.S., et al. Hyperamylasemia after post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 154 (1995) 1373-1375
44. Baniel J., Foster R.S., Rowland R.G., et al. Complications of primary retroperitoneal lymph node dissection. J Urol 152 (1994) 424-427
45. Foster R.S., and Donohue J.P. Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. J Urol 163 (2000) 1788-1792
46. Donohue J.P., Foster R.S., Rowland R.G., et al. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144 (1990) 287-291 [discussion 91-2]
47. Jewett M.A., Kong Y.S., Goldberg S.D., et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 139 (1988) 1220-1224
48. Chang S.S., Smith Jr. J.A., Girasole C., et al. Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection. J Urol 168 (2002) 87-92
49. Leibovitch I., Nash P.A., Little Jr. J.S., et al. Spinal cord ischemia after post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell cancer. J Urol 155 (1996) 947-951
50. Donat S.M. Peri-operative care in patients treated for testicular cancer. Semin Surg Oncol 17 (1999) 282-288
51. Loehrer Sr. P.J., Williams S.D., and Einhorn L.H. Testicular cancer: the quest continues. J Natl Cancer Inst 80 (1988) 1373-1382
52. Einhorn L.H., and Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87 (1977) 293-298
53. Einhorn L.H., and Donohue J.P. Chemotherapy for disseminated testicular cancer. Urol Clin North Am 4 (1977) 407-426
54. Chaudhary U.B., and Haldas J.R. Long-term complications of chemotherapy for germ cell tumours. Drugs 63 (2003) 1565-1577
55. Loehrer Sr. P.J., Einhorn L.H., and Williams S.D. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4 (1986) 528-536
56. Gilligan T. Complications of systemic therapy for genitourinary malignancies. AUA Update Series 24 (2005)
57. de Wit R., Roberts J.T., Wilkinson P.M., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer genitourinary tract cancer cooperative group and the Medical Research council. J Clin Oncol 19 (2001) 1629-1640
58. Ratliff T.R., and Williams R.D. Hemorrhagic cystitis, chemotherapy, and bladder toxicity. J Urol 159 (1998) 1044
59. Dietrich J., Marienhagen J., Schalke B., et al. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother 38 (2004) 242-246
60. Bokemeyer C., and Schmoll H.J. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11 (1993) 1703-1709
61. Travis L.B., Curtis R.E., Storm H., et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89 (1997) 1429-1439
62. Pedersen-Bjergaard J., Daugaard G., Hansen S.W., et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338 (1991) 359-363
63. Kollmannsberger C., Kuzcyk M., Mayer F., et al. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 17 (1999) 275-281
64. Wanderas E.H., Fossa S.D., and Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 33 (1997) 253-262
65. Fossa S.D., Aass N., Winderen M., et al. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 13 (2002) 222-228
66. Osanto S., Bukman A., Van Hoek F., et al. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 10 (1992) 574-579
67. Boyer M., Raghavan D., Harris P.J., et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 8 (1990) 21-26
68. Hartmann J.T., Kollmannsberger C., Kanz L., et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 83 (1999) 866-869
69. Thompson S.W., Davis L.E., Kornfeld M., et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54 (1984) 1269-1275
70. Hansen S.W., Helweg-Larsen S., and Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 7 (1989) 1457-1461
71. Roth B.J., Greist A., Kubilis P.S., et al. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol 6 (1988) 1239-1247
72. van der Hulst R.J., Dreschler W.A., and Urbanus N.A. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 97 (1988) 133-137
73. Bokemeyer C., Berger C.C., Hartmann J.T., et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77 (1998) 1355-1362
74. Ginsberg S.J., and Comis R.L. The pulmonary toxicity of antineoplastic agents. Semin Oncol 9 (1982) 34-51
75. White D.A., and Stover D.E. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. Chest 86 (1984) 723-728
76. Goldiner P.L., and Schweizer O. The hazards of anesthesia and surgery in bleomycin-treated patients. Semin Oncol 6 (1979) 121-124
77. Donat S.M., and Levy D.A. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?. J Urol 160 (1998) 1347-1352
78. Fossa S.D., Lehne G., Heimdal K., et al. Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology 52 (1995) 300-305
79. Vogelzang N.J., Bosl G.J., Johnson K., et al. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95 (1981) 288-292
80. Meinardi M.T., Gietema J.A., van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18 (2000) 1725-1732
81. Doll D.C., Ringenberg Q.S., and Yarbro J.W. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 4 (1986) 1405-1417
82. Huddart R.A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21 (2003) 1513-1523
83. Fossa S.D. Long-term sequelae after cancer therapy-survivorship after treatment for testicular cancer. Acta Oncol 43 (2004) 134-141
84. Nuver J., Smit A.J., Sleijfer D.T., et al. Left ventricular and cardiac autonomic function in survivors of testicular cancer. Eur J Clin Invest 35 (2005) 99-103
85. Icli F., Karaoguz H., Dincol D., et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 72 (1993) 587-593
86. Licciardello J.T., Moake J.L., Rudy C.K., et al. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 42 (1985) 296-300
87. Ariceta G., Rodriguez-Soriano J., Vallo A., et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 28 (1997) 35-40
88. Lajer H., Bundgaard H., Secher N.H., et al. Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin. Br J Cancer 89 (2003) 1633-1637
89. Lajer H., and Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 25 (1999) 47-58
90. Nuver J., Smit A.J., Wolffenbuttel B.H., et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23 (2005) 3718-3725
91. Nijman J.M., Schraffordt Koops H., Oldhoff J., et al. Sexual function after surgery and combination chemotherapy in men with disseminated nonseminomatous testicular cancer. J Surg Oncol 38 (1988) 182-186
92. Lampe H., Horwich A., Norman A., et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15 (1997) 239-245
93. Huyghe E., Matsuda T., Daudin M., et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 100 (2004) 732-737
94. Brydoy M., Fossa S.D., Klepp O., et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 97 (2005) 1580-1588
95. Huddart R.A., Norman A., Moynihan C., et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 93 (2005) 200-207
96. DeSantis M., Albrecht W., Holtl W., et al. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer 83 (1999) 864-865
97. Pont J., Albrecht W., Postner G., et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14 (1996) 441-448
98. Bohlen D., Burkhard F.C., Mills R., et al. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 165 (2001) 441-444
99. Lee S.J., Schover L.R., Partridge A.H., et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24 (2006) 2917-2931
100. Girasole C, Cookson MS, Smith Jr JA, et al. Sperm banking: use and outcomes in patients treated for testicular cancer. In: Program and abstracts of the American Urologic Association annual meeting. Atlanta (GA), 2006. p. 148 [abstract 456].
101. van den Berkmortel F., de Wit R., de Rooy J., et al. Osteonecrosis in patients with testicular tumours treated with chemotherapy. Neth J Med 62 (2004) 23-27
102. Loutfi R., Kattan J., and Kikano T. Spontaneous pneumothorax following chemotherapy for metastatic germ cell tumor: a case report. J Med Liban 52 (2004) 115-117
103. Uygur M.C., and Ozen H. Gynecomastia following chemotherapy for testicular cancer. Urol Int 70 (2003) 253-254
104. Classen J., Schmidberger H., Meisner C., et al. Radiotherapy for stages IIa/b testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21 (2003) 1101-1106
105. Bamberg M., Schmidberger H., Meisner C., et al. Radiotherapy for stages I and IIa/b testicular seminoma. Int J Cancer 83 (1999) 823-827
106. Zagars G.K., Ballo M.T., Lee A.K., et al. Mortality after cure of testicular seminoma. J Clin Oncol 22 (2004) 640-647
107. Chao C.K., Lai P.P., Michalski J.M., et al. Secondary malignancy among seminoma patients treated with adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 33 (1995) 831-835
108. Peckham M.J., Barrett A., Husband J.E., et al. Orchidectomy alone in testicular stage I non-seminomatous germ-cell tumours. Lancet 2 (1982) 678-680
109. Thomas J., Aleman M., Dreicer R., et al. Management of stage I nonseminomatous germ-cell tumors. Semin Urol Oncol 20 (2002) 220-226
110. Theodorescu D., Rabbani F., and Donat S.M. Follow-up of genitourinary malignancies for the office urologist: a practical approach. Part 2: kidney cancer and germ cell cancer of the testis. AUA Update Series 23 (2004)
111. Sturgeon J.F., Jewett M.A., Alison R.E., et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 10 (1992) 564-568
112. Chang S.S., and Sheinfeld J. Clinical stage I nonseminomatous germ cell tumors: treatment options. AUA Update Series 20 (2001)
113. Sogani P.C., Perrotti M., Herr H.W., et al. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 159 (1998) 855-858
114. Nicolai N., and Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J Urol 154 (1995) 1045-1049
115. Fossa S.D., Jacobsen A.B., Aass N., et al. How safe is surveillance in patients with histologically low-risk non-seminomatous testicular cancer in a geographically extended country with limited computerised tomographic resources?. Br J Cancer 70 (1994) 1156-1160
116. Koch M.O. Cost-effective strategies for the follow-up of patients with germ cell tumors. Urol Clin North Am 25 (1998) 495-502
117. Mykletun A., Dahl A.A., Haaland C.F., et al. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 23 (2005) 3061-3068
118. Thorsen L., Nystad W., Dahl O., et al. The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer 39 (2003) 1216-1221